Filter Results:
(1,253)
Show Results For
- All HBS Web
(1,253)
- People (5)
- News (177)
- Research (922)
- Events (6)
- Multimedia (12)
- Faculty Publications (754)
Show Results For
- All HBS Web
(1,253)
- People (5)
- News (177)
- Research (922)
- Events (6)
- Multimedia (12)
- Faculty Publications (754)
- 25 Jun 2019
- Blog Post
Learning the Language of Business and Science – The MS/MBA Biotechnology: Life Sciences Program
pharmaceutical company. I then chose to go to HBS to get my first formal training in business. This has helped me to become fluent in the language of business, evaluate strategic decisions through a different lens, and grow my network... View Details
- September 2024
- Case
Myeloma Investment Fund
By: Kyle Myers and Scott Sawaya
This case explores a critical decision facing the Myeloma Investment Fund (MIF) as it evaluates two investment opportunities aimed at accelerating a cure for multiple myeloma.
The MIF, a venture philanthropy fund, must choose between two distinct paths. One... View Details
The MIF, a venture philanthropy fund, must choose between two distinct paths. One... View Details
Keywords: Venture Philanthropy; Biomedical Research; Investing For Impact; Innovation ＆ Entrepreneurship; Venture Capital; Science-Based Business; Philanthropy and Charitable Giving; Decision Making; Health Care and Treatment; Pharmaceutical Industry; Pharmaceutical Industry
Myers, Kyle, and Scott Sawaya. "Myeloma Investment Fund." Harvard Business School Case 625-047, September 2024.
- February 2015 (Revised November 2015)
- Supplement
Building an Integrated Biopharma Company: Crucell (B)
By: Richard G. Hamermesh, Marianne Van Der Steen and Susan Harmeling
The Crucell (B) case updates events at Crucell since 2009. In September, 2009, Johnson & Johnson acquired 18% of Crucell for $400 million. This investment was part of a business development deal. Subsequently, in 2012, Johnson & Johnson acquired Crucell for $2.8... View Details
Keywords: Biotechnology; Biopharmacy Company; Licensing Agreements In Biopharmacy; Licensing; Human Cell-line Technology; Vaccine; Healthcare Innovation; Global Health; Entrepreneurship; Health Care and Treatment; Acquisition; Innovation and Invention; Pharmaceutical Industry; Pharmaceutical Industry
Hamermesh, Richard G., Marianne Van Der Steen, and Susan Harmeling. "Building an Integrated Biopharma Company: Crucell (B)." Harvard Business School Supplement 815-086, February 2015. (Revised November 2015.)
- July 2014
- Teaching Note
Vaxess Technologies, Inc.
By: John A. Quelch
- June 2013
- Supplement
Can PACIV (Puerto Rico) Serve European Customers? (Video Supplement)
By: Jim Sharpe
This is Video Supplement for Can PACIV (Puerto Rico) Serve European Customers? HBS Case #808099. View Details
Keywords: Entrepreneurial Management; Global Organizations; Service; Hiring; Incentives, Motivation; Joint Ventures; Customer Service Excellence; Customer Relationship Management; Empowerment; International Expansion; Ownership Structure; Culture; Organization Alignment; Growth and Development Strategy; Entrepreneurship; Private Ownership; Globalized Markets and Industries; Globalized Firms and Management; Pharmaceutical Industry; Pharmaceutical Industry; Puerto Rico; United Kingdom
Sharpe, Jim. "Can PACIV (Puerto Rico) Serve European Customers? (Video Supplement)." Harvard Business School Video Supplement 813-722, June 2013.
- May 2013
- Supplement
Can PACIV (Puerto Rico) Serve European Customers?
This is the Spreadsheet Supplement HBS Case #808099 (PACIV). Includes Exhibit 1a, Exhibit 1b, Exhibit 1c, Exhibit 1d, Exhibit 1e, Exhibit 1f, Exhibit 5, Exhibit 6, and Exhibit 8. View Details
Keywords: Entrepreneurs; Foreign Subsidiaries; Global Business; International Business; International Entrepreneurial Finance; International Operations; Entrepreneurship; Globalization; International Finance; Operations; Finance; Pharmaceutical Industry; Pharmaceutical Industry; Puerto Rico; United Kingdom; Europe; United States
- November 2011 (Revised February 2012)
- Case
China Novartis Institute for Biomedical Research: Building a Sustainable, Globally Integrated Research Enterprise
By: Vicki Sato, Christoph Jaeker and Pooja Mehta Solanki
As the head of the Novartis Institute for Biomedical Research in China, En Li was shepherding a $1 billion R&D investment in China. So far he had been able to attract a large number of Chinese-born but US-trained scientists to play a critical role in establishing the... View Details
Keywords: Globalized Firms and Management; Research; Corporate Strategy; Pharmaceutical Industry; Pharmaceutical Industry; China
Sato, Vicki, Christoph Jaeker, and Pooja Mehta Solanki. "China Novartis Institute for Biomedical Research: Building a Sustainable, Globally Integrated Research Enterprise." Harvard Business School Case 612-048, November 2011. (Revised February 2012.)
- April 2010
- Teaching Note
Wyeth Pharmaceuticals: Spurring Scientific Creativity with Metrics
Teaching Note for [607008]. View Details
- October 2009 (Revised July 2013)
- Case
Gilead Sciences, Inc.: Access Program
By: V. Kasturi Rangan and Katharine Lee
Gilead Sciences, the U.S. leader in HIV/AIDS medicines, with global sales of $5.4 billion in 2009, had undertaken several innovative actions to make its anti-viral products available to over 100 low- and middle-income countries. Having reached nearly 680,000 patients... View Details
Keywords: Health Care and Treatment; Emerging Markets; Product; Sales; Competitive Strategy; Pharmaceutical Industry; Pharmaceutical Industry
Rangan, V. Kasturi, and Katharine Lee. "Gilead Sciences, Inc.: Access Program." Harvard Business School Case 510-029, October 2009. (Revised July 2013.)
- March 2009
- Teaching Note
Proteus Biomedical: Making Pigs Fly (TN)
Teaching Note for [809051]. View Details
- June 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (D)
By: Sandra J. Sucher and Stacy McManus
Supplements the (A) and (B) cases. View Details
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (D)." Harvard Business School Case 603-046, June 2003. (Revised October 2004.)
- June 1999 (Revised June 2000)
- Case
Eckerd Corporation
By: Michael E. Porter and John E. Kelleher
Describes the history and current situation in the retail pharmacy industry, including competition from new merchants and Internet drugstores. Eckerd, one of the top four drug chains, must decide how to position itself for the future. View Details
Keywords: Competition; Alignment; Supply and Industry; Pharmaceutical Industry; Pharmaceutical Industry
Porter, Michael E., and John E. Kelleher. "Eckerd Corporation." Harvard Business School Case 799-141, June 1999. (Revised June 2000.)
- 30 Oct 2007
- First Look
First Look: October 30, 2007
Changing Context of Pharmaceutical Risk Mitigation Author:Arthur A. Daemmrich Periodical:Pharmacy in History 49, no. 2 (2007): 61-75 Abstract In the wake of Vioxx, Avandia, and other recent prominent cases of drugs found to cause side... View Details
Keywords: Sean Silverthorne
- 04 Feb 2019
- Blog Post
Presenting…an Alternative to Company Presentations: Evercore Grabs Attention with Interactive Events
case study. When they added two more ingredients to the recipe – a focus on a familiar industry, amplified by media exposure the audience would recognize – they arrived at the heart of their presentation; a “live” case study about Evercore’s role in a recent M&A:... View Details
- 01 Oct 1998
- News
Going Against the Flow
500 automobile, chemical, and pharmaceutical companies that actually run businesses here. Those latter companies know the market and have done very well as a result. "If you're going to invest in emerging markets," he continues, "you also... View Details
Keywords: Dun Gifford, Jr.
- 01 Mar 2012
- News
How to Close the Health Gap
real progress has been made over the last decade, thanks in part to funding from organizations such as the Bill & Melinda Gates Foundation and efforts by pharmaceutical companies and governments to make drugs available at little or no... View Details
- 23 Mar 2010
- First Look
First Look: March 23
catastrophic risks to patients, physicians, pharmaceutical firms, and regulators. Between the early 1960s and the present, national systems were built to collect, standardize, and respond to individual reports of side effects, with the... View Details
Keywords: Martha Lagace
- 17 Jan 2008
- Working Paper Summaries
Competition in Modular Clusters
- November 2023 (Revised April 2024)
- Case
BiomX: Bringing Phage Back to the Stage
By: Paul A. Gompers, Elie Ofek, Orna Dan and Emilie Billaud
In the spring of 2023, and following the favorable results of a trial involving its phage cocktail for treating lung infections among cystic fibrosis (CF) patients, the leadership of BiomX had several critical issues to wrestle with. First, given its precarious... View Details
Keywords: Working Capital; Financing and Loans; Health Testing and Trials; Product Development; Research and Development; Science-Based Business; Commercialization; Pharmaceutical Industry; Pharmaceutical Industry
Gompers, Paul A., Elie Ofek, Orna Dan, and Emilie Billaud. "BiomX: Bringing Phage Back to the Stage." Harvard Business School Case 524-051, November 2023. (Revised April 2024.)